We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
- Authors
Wilding, J P H; Woo, V; Rohwedder, K; Sugg, J; Parikh, S; Dapagliflozin 006 Study Group
- Abstract
Dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), has been shown to improve glycaemic control, stabilize insulin dosing and mitigate insulin-associated weight gain over 48 weeks in patients whose type 2 diabetes mellitus (T2DM) was inadequately controlled despite high doses of insulin. Here the efficacy and safety of dapagliflozin therapy after a total of 104 weeks are evaluated in this population.
- Publication
Diabetes, obesity & metabolism, 2014, Vol 16, Issue 2, p124
- ISSN
1463-1326
- Publication type
Journal Article
- DOI
10.1111/dom.12187